Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma

Despite advances in cancer management, hepatocellular carcinoma (HCC) remains the sixth most common malignancy and the second leading cause of cancer-related death worldwide (1,2). While surgical resection remains the mainstay of the curative treatment approach, patients with unresectable cancer or poor hepatic reserve secondary to chronic liver disease often cannot undergo this procedure. As such, multiple liver-directed treatment options are utilized including radioembolization of the lesion(s) (3). To assess the degree to which patients will tolerate these liver-directed treatments, various laboratory and scoring systems exist